Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.

NCT07411378 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

164

Enrollment

INDUSTRY

Sponsor class

Conditions

Muscle Wasting
Obesity & Overweight
Obesity

Interventions

DRUG: BIO101
OTHER: Placebo
DRUG: Semaglutide

Sponsor

Biophytis